Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2013

TSRI, Janssen Team Up on Infectious Disease Research

  • The Scripps Research Institute (TSRI) and Janssen Pharmaceuticals are collaborating on infectious disease research, with an initial project focusing on influenza, the organizations today announced.

    Under the terms of this five-year agreement, Janssen is entitled to certain license rights, and will contribute research assistance through its Crucell Vaccine Institute. This collaboration builds on previous research on the influenza virus conducted jointly by TSRI and Janssen. Financial terms of the collaboration were not disclosed.

    "We're delighted to partner with Janssen in this work that could have a significant impact on human health," Michael Marletta, TSRI president and CEO, said in a statement. "The new agreement leverages the institute's significant strengths in structural biology to move forward new therapies and vaccines."



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »